Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group [...] ABSTRACT Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group
1 January 2026 in Archives of Endocrinology and Metabolism
Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate [...] ABSTRACT Objective: To evaluate remission and relapse rates in patients with Graves’ disease treated with methimazole and to identify clinical and laboratory predictors of these outcomes. Subjects and methods: We conducted a retrospective cohort study of 425 adult patients newly diagnosed with Graves’ disease at a single tertiary center between 2002 and 2022. All patients received methimazole for at least 12 months. Remission was defined as drug-free biochemical euthyroidism for 12 months or longer after therapy withdrawal. Univariate and multivariate